The responses of HNSCC patients to immunotherapy are shown by two novel co-expression patternsNarmeen Daher-Ghanem, Nataly Kravchenko‐Balasha, Marcus Couey et al.|npj Precision Oncology|2025Cited by 2
Abstract A025: Direct <i>in vivo</i> CRISPR screen identifies <i>BAP1</i> and <i>FAT1</i> as potent tumor suppressors in sarcomagenesisJianguo Huang, David G. Kirsch, Xingliang Liu et al.|Cancer Research|2025Cited by 0
Abstract 6707: Direct <i>in vivo</i> CRISPR screen identifies <i>BAP1</i> and <i>FAT1</i> as potent tumor suppressors in sarcomagenesisJianguo Huang, David G. Kirsch, Xingliang Liu et al.|Cancer Research|2025Cited by 0
A tailored <i>in vivo</i> CRISPR screen identifies <i>BAP1</i> as a potent tumor suppressor of soft tissue sarcomaJianguo Huang, David G. Kirsch, Xingliang Liu et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0
CMS subtypes correlate with complete response in trial of neoadjuvant Galunisertib plus chemoradiation in rectal cancerVenkatesh Rajamanickam, Kristina H. Young, Noah D. Simons et al.|Translational Oncology|2026Cited by 0